These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11006134)

  • 1. Farnesyl transferase inhibitors: current developments and future perspectives.
    Eskens FA; Stoter G; Verweij J
    Cancer Treat Rev; 2000 Oct; 26(5):319-32. PubMed ID: 11006134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
    Girgert R; Hohnecker A; Wittrock J; Schweizer P
    Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular forceps from combinatorial libraries prevent the farnesylation of Ras by binding to its carboxyl terminus.
    Dong DL; Liu R; Sherlock R; Wigler MH; Nestler HP
    Chem Biol; 1999 Mar; 6(3):133-41. PubMed ID: 10074468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyl-derived inhibitors of ras farnesyl transferase.
    Kang MS; Stemerick DM; Zwolshen JH; Harry BS; Sunkara PS; Harrison BL
    Biochem Biophys Res Commun; 1995 Dec; 217(1):245-9. PubMed ID: 8526918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current progress on farnesyl protein transferase inhibitors.
    Singh SB; Lingham RB
    Curr Opin Drug Discov Devel; 2002 Mar; 5(2):225-44. PubMed ID: 11926129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors.
    Wittrock J; Schweizer P; Girgert R
    Anticancer Res; 2002; 22(6C):4205-9. PubMed ID: 12553057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and biological analyses of farnesyl-protein transferase inhibitors.
    Kohl NE; Koblan KS; Omer CA; Oliff A; Gibbs JB
    Methods Mol Biol; 1998; 84():283-91. PubMed ID: 9666457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mob-1, a Ras target gene, is overexpressed in colorectal cancer.
    Zhang R; Zhang H; Zhu W; Pardee AB; Coffey RJ; Liang P
    Oncogene; 1997 Apr; 14(13):1607-10. PubMed ID: 9129152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ras farnesyltransferase inhibition: a novel and safe approach for cancer chemotherapy.
    Nammi S; Lodagala DS
    Acta Pharmacol Sin; 2000 May; 21(5):396-404. PubMed ID: 11324435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. v-Src transformation is mediated through farnesylated proteins.
    Teng S; Sun J; Irby R; Hamilton AD; Sebti S; Yeatman TJ
    J Surg Res; 2001 Aug; 99(2):343-6. PubMed ID: 11469908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
    Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
    Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.
    Njoroge FG; Vibulbhan B; Pinto P; Strickland C; Kirschmeier P; Bishop WR; Girijavallabhan V
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5877-80. PubMed ID: 15501060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer.
    Johnston SR
    Lancet Oncol; 2001 Jan; 2(1):18-26. PubMed ID: 11905614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Developments in chemotherapy; cytostatic agents with an increased specificity and other forms of administering cytotoxic antineoplastic agents].
    Eskens FA; de Jonge MJ; Verweij J
    Ned Tijdschr Geneeskd; 2001 Nov; 145(46):2208-13. PubMed ID: 11757242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using inhibitors of prenylation to block localization and transforming activity.
    Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
    Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent and selective farnesyl transferase inhibitors.
    Millet R; Domarkas J; Houssin R; Gilleron P; Goossens JF; Chavatte P; Logé C; Pommery N; Pommery J; Hénichart JP
    J Med Chem; 2004 Dec; 47(27):6812-20. PubMed ID: 15615530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.